{"References": [{"title": "Pharmacogenetics of antiplatelet therapy: ready for clinical application?", "authors": "Jessica L. Mega, Marc S. Sabatine, Deepak L. Bhatt", "journal": "Circulation", "year": "2010", "volumes": "121", "first page": "1641", "last page": "1653", "DOI": "10.1161/CIRCULATIONAHA.109.888313"}, {"title": "CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis", "authors": "Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS", "journal": "JAMA", "year": "2010", "volumes": "304", "first page": "1821", "last page": "1830", "DOI": "10.1001/jama.2010.1543"}, {"title": "Pharmacogenomics of antiplatelet therapy: how much evidence is enough for clinical implementation?", "authors": "Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L", "journal": "Journal of Thrombosis and Haemostasis", "year": "2009", "volumes": "7", "first page": "375", "last page": "380", "DOI": "10.1111/j.1538-7836.2009.03309.x"}, {"title": "Genetic determinants of response to clopidogrel and cardiovascular events", "authors": "Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA", "journal": "The New England Journal of Medicine", "year": "2009", "volumes": "360", "first page": "363", "last page": "375", "DOI": "10.1056/NEJMoa0808227"}, {"title": "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study", "authors": "Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G", "journal": "The Lancet", "year": "2009", "volumes": "373", "first page": "309", "last page": "317", "DOI": "10.1016/S0140-6736(08)61845-0"}, {"title": "Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant?", "authors": "Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von Beckerath N, Kastrati A", "journal": "European Heart Journal", "year": "2010", "volumes": "31", "first page": "1086", "last page": "1090", "DOI": "10.1093/eurheartj/ehp552"}, {"title": "Impact of CYP2C19 polymorphism on antiplatelet therapy with clopidogrel", "authors": "Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P", "journal": "Pharmacogenomics", "year": "2006", "volumes": "7", "first page": "511", "last page": "519", "DOI": "10.2217/14622416.7.4.511"}, {"title": "Pharmacogenetics of clopidogrel: relevance to genetic testing", "authors": "Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR", "journal": "Clinical Pharmacology & Therapeutics", "year": "2011", "volumes": "89", "first page": "352", "last page": "359", "DOI": "10.1038/clpt.2010.287"}, {"title": "Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial", "authors": "Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, Hochholzer W, Valgimigli M, Wiviott SD, Neumann FJ", "journal": "International Journal of Cardiology", "year": "2013", "volumes": "168", "first page": "3716", "last page": "3722", "DOI": "10.1016/j.ijcard.2013.06.014"}, {"title": "The role of pharmacogenomics in antiplatelet therapy", "authors": "Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P, Hernández R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Costa MA, Bass TA, Macaya C", "journal": "Pharmacogenomics", "year": "2007", "volumes": "8", "first page": "927", "last page": "937", "DOI": "10.2217/14622416.8.8.927"}]}